RESTON, Va. – Breast-conserving surgery (BCS) is the primary treatment for early-stage breast cancer, but more accurate techniques are needed to assess resection margins during surgery to avoid the need for follow-up surgeries. Now, in a first-in-human study, British researchers have provided a possible solution using Cerenkov luminescence imaging (CLI), which combines optical and molecular imaging by detecting light emitted by the PET radiotracer F-18-fluorodeoxyglucose (F-18-FDG). CLI's high-resolution and small-sized imaging equipment make it a promising technology for assessing tumor margins during breast tumor surgery. The study is covered in the featured article of The Journal of Nuclear Medicine's June 2017 issue.
"Currently, approximately 1 in 5 women who undergo breast-conserving surgery, also known as lumpectomy, require repeat surgery due to inadequate excision of the tumor during the initial surgical procedure," explains Arnie D. Purushotham, MD, professor at King's College London, UK. "By accurately assessing tumor resection margins intraoperatively with CLI, surgeons may be able to completely clear the cancer with a single operation, thereby reducing the number of breast cancer patients requiring a second, or even third, surgical procedure. Ultimately this could lead to improved patient care and reduced healthcare costs if confirmed in larger clinical studies."
This study included 22 patients with invasive breast cancer. F-18-FDG was injected 45-60 minutes before surgery. Immediately after the excision of tumors, specimens were imaged intraoperatively in an investigational CLI imaging system. The first 10 patients were used to optimize the imaging protocol; the remaining 12 were included in the analysis dataset. Ten of the 12 patients had an elevated tumor radiance on CLI, and agreement among raters on margin distance was good. Sentinel lymph nodes, which used technetium-99m to facilitate identification, were successfully detected and biopsied in all patients.
F-18-FDG CLI is, therefore, a promising, low-risk technique for intraoperative assessment of tumor margins in breast-conserving surgery. A randomized controlled trial will evaluate the impact of this technique on re-excision rates.
Purushotham points out, "The feasibility of intraoperative CLI as shown in this study, in combination with the wide applicability of F-18-FDG across a range of solid cancers, provides a stepping stone for clinical evaluation of this technology in other solid cancer types that also experience incomplete tumor resection due to close or involved margins." He also notes, "CLI offers the ability to image clinically approved and widely used PET tracers intraoperatively by using small-sized imaging equipment, thus expanding the field of traditional nuclear medicine."
###
The authors of "Intraoperative Assessment of Tumor Resection Margins in Breast-Conserving Surgery using 18F-FDG Cerenkov Luminescence Imaging – A First-in-Human Feasibility Study" include Maarten R. Grootendorst, Massimiliano Cariati, Michael Douek, and Arnie Purushotham, Kings College London and Guy's and St. Thomas NHS Foundation Trust, London, UK; Sarah E. Pinder, Julie Owen, Mieke Van Hemelrijck, and Gary J. Cook, Kings College London; Ashutosh Kothari, Tibor Kovacs, Hisham Hamed, Amit Pawa, Fiona Nimmo, Vernie Ramalingam, Sweta Sethi, Sanjay Mistry, Chris Sibley-Allen, and Sarah Allen, Guy's and St. Thomas' NHS Foundation Trust; Kunal Vyas, Sagentia Ltd., Cambridge, UK; David S. Tuch, Lightpoint Medical Ltd., Chesham, UK; and Alan Britten, St. George's Hospital, London, UK.
Please visit the SNMMI Media Center (http://www.snmmi.org/Media.aspx) to view the PDF of the study, including images, and more information about molecular imaging and personalized medicine. To schedule an interview with the researchers, please contact Laurie Callahan at (703) 652-6773 or [email protected]. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.
SNMMI's more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit http://www.snmmi.org.
Media Contact
Laurie Callahan
[email protected]
@SNM_MI
http://www.snm.org
############
Story Source: Materials provided by Scienmag